New combo therapy targets recurrent lung cancer without surgery
NCT ID NCT04505267
First seen Nov 11, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This early-stage study tests a drug called NBTXR3, which boosts the effects of radiation on cancer cells, in people with non-small cell lung cancer that has returned and cannot be surgically removed. About 34 participants will receive the drug injected into the tumor followed by radiation. The goal is to find the safest dose and see if this approach can kill cancer cells while sparing healthy tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.